ASCT2 inhibits HIV-1 infectivity by promoting the incorporation of a gp160/ASCT2 complex into virions
ABSTRACT Restriction factors are type I interferon (IFN)-inducible proteins that provide an early line of defense against HIV-1. Our current findings propose the amino acid transporter ASCT2 as a new host plasma membrane transporter that restricts the infectivity of HIV-1 viral particles. Our result...
Saved in:
| Main Authors: | Luciana Morellatto Ruggieri, Eri Miyagi, Sandra Kao, Hideki Saito, Aymé Drake Figueredo, Haruki Kitamura, María I. Colombo, Klaus Strebel |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
American Society for Microbiology
2025-08-01
|
| Series: | mBio |
| Subjects: | |
| Online Access: | https://journals.asm.org/doi/10.1128/mbio.01465-25 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Retrospective claims data analysis of ASCT characteristics and costs for working-age, multiple myeloma patients in the US, 2017–2019
by: Whanhui Chi, et al.
Published: (2025-01-01) -
THE TREATMENT OF MULTIPLE MYELOMA PATIENTS NOT ELIGIBLE FOR ASCT
by: Anuj Mahindra, et al.
Published: (2010-05-01) -
Adaptor Protein Complexes in HIV-1 Pathogenesis: Mechanisms and Therapeutic Potential
by: Maria Elena Barone, et al.
Published: (2025-05-01) -
Updated analysis of EMN02 demonstrated overall survival benefit to early ASCT for multiple myeloma
by: Alfred L. Garfall
Published: (2025-01-01) -
Long‐term results of the FIL MCL0208 trial of lenalidomide maintenance versus observation after ASCT in MCL patients
by: Rita Tavarozzi, et al.
Published: (2025-03-01)